Fangda represented HLC on the deal. Viva Biotech Holdings Group completed the equity financing at both Viva Holdings and its subsidiary Viva Biotech (Shanghai) Ltd., bringing in...
You must be a Standard 1 Year member to access this content.
Fangda advised WuXi XDC Cayman Inc. on the deal. WuXi XDC Cayman Inc. successfully spun-off from WuXi Biologics (Cayman) Inc. for a separate listing on the Main...
You must be a Standard 1 Year member to access this content.
Clifford Chance advised Huaxin Cement Co., Ltd., Fangda and Grandall advised Shenwan Hongyuan Capital (H.K.) Limited. Huaxin Cement Co., Ltd. announced its B to H Share listing...
You must be a Standard 1 Year member to access this content.
Fangda and Harneys advised Chaoju Eye Care Holdings Limited on the deal. Chaoju Eye Care Holdings raised HK$1.36 billion ($175.1 million) in net proceeds from its Hong...
You must be a Standard 1 Year member to access this content.
